Understanding Generic Drugs
With the onset of the patent expiration on Gleevec of the patent expiration on Gleevec for CML expiring in July and for GIST in June 2022 in the United States, it becomes more important than ever [...]
UK Pulls Stivarga From Cancer Drug Fund Endangering GIST Patients
The National Health Service (NHS) in the United Kingdom has announced plans to halt funding through the Cancer Drug Fund for regorafenib (Stivarga), thereby preventing GIST patients from having access to this life-saving medication.We at [...]
GIST Cancer Journal Winter Issue Out!
The Life Raft Group is pleased to announce the release of the fourth issue of The GIST Cancer Journal, the official journal of the Life Raft Group and the first academic journal devoted solely to GIST. [...]
Protein Complex Believed To Be Cancer-Causing Gene
A recent study from MD Anderson provides insight into a protein complex that plays a significant role in cancer.In the study at the University of Texas MD Anderson Cancer center, similarities were drawn between bean [...]
Clinical Registry Study Planned by ASCO
American Society of Clinical Oncology (ASCO) is planning its first-ever clinical registry study, the Targeted Agent and Profiling Utilization Registry (TAPUR). ASCO plans should increase patient access to off-label drugs and match patients with [...]
Plasma Level Testing for Imatinib Now Available
Saladax Biomedical, a CLIA certified laboratory based in Bethlehem, Pennsylvania, is now providing plasma level testing for imatinib.(Gleevec). Testing is currently free of charge through January 31, 2015, as it is not covered by [...]
Strategies to rapidly identify and validate new therapies for GIST
By Dr. Anette Duensing, University of Pittsburgh Cancer Institute, and Dr. Maria Debiec-Rychter, KU Leuven, Belgium, LRG Research Team Dr. Maria Debiec-Rychter Dr. Anette Duensing Although most GISTs initially respond well [...]
Pfizer Releases New Dosage for Sutent Patients
Sutent 37.5 mg Ease of use and lower costs may be on the horizon for Sutent patients who are currently on a 37.5 milligram prescription. Available now, Pfizer has released a new [...]
Recent Study Discusses Alternative Schedules for Sutent
A recent study published in Oncology Letters, discusses the importance of effective therapy management of sunitinib (Sutent)
Merck’s Keytruda Approved for Advanced Melanoma Treatment
Advanced Melanoma patients are now able to take a powerful new immuno-cology drug from Merck called Keytruda.